Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis
Open Access
- 14 April 2010
- journal article
- review article
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2010, 1-9
- https://doi.org/10.1155/2010/568396
Abstract
Despite a decrease in mortality over the last decade, sepsis remains the tenth leading causes of death in western countries and one of the most common cause of death in intensive care units. The recent discovery of Toll-like receptors and their downstream signalling pathways allowed us to better understand the pathophysiology of sepsis-related disorders. Particular attention has been paid to Toll-like receptor 4, the receptor for Gram-negative bacteria outer membrane lipopolysaccharide or endotoxin. Since most of the clinical trial targeting single inflammatory cytokine in the treatment of sepsis failed, therapeutic targeting of Toll-like receptor 4, because of its central role, looks promising. The purpose of this paper is to focus on the recent data of various drugs targeting TLR4 expression and pathway and their potential role as adjunctive therapy in severe sepsis and septic shock.Keywords
This publication has 94 references indexed in Scilit:
- Evidence that opioids may have toll-like receptor 4 and MD-2 effectsBrain, Behavior, and Immunity, 2010
- Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic CellsImmunity, 2009
- Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1β gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cellsToxicology and Applied Pharmacology, 2009
- Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4Proceedings of the National Academy of Sciences of the United States of America, 2009
- Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9Nature Immunology, 2008
- Nicotine exposure alters in vivo human responses to endotoxinClinical and Experimental Immunology, 2006
- Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-κB phosphorylation and nuclear factor-κB transcriptional activity through nicotinic acetylcholine receptor α7Clinical and Experimental Immunology, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006
- Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammationNature, 2002
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001